Clinical sales revenue continues to accelerate as the company opens SneakPeek to new channels.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, has achieved a milestone of over 500 distributors of its SneakPeek Clinical test across the US and UK. Originally focusing on medical offices, the company has expanded its early gender DNA test offering to independent labs that carry a range of genetic tests.
This expansion makes accurate, affordable fetal sex determination at 8 weeks into pregnancy available to Australian families for the first time.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces that the SneakPeek DNA test is now available to Australian mums to learn the gender of their babies as early as 8 weeks into pregnancy.
Gateway Genomics Continues Upward Momentum in Q4 2019 With Over 150,000 SneakPeek Early Gender DNA Tests Sold
The prominent sales milestone was achieved this month as clinical revenue accelerates and the company prepares to launch SneakPeek in Australia.
Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, reached 150,000 SneakPeek Early Gender DNA Tests sold, just five months after attaining the 100,000-test landmark in June.
Gateway Genomics Attending American College of Osteopathic Obstetricians & Gynecologists (ACOOG) 2019 Fall Conference to Present SneakPeek Clinical Early Gender DNA Test
Non-invasive prenatal test SneakPeek Clinical determines fetal sex at 8 weeks gestational age, weeks to months earlier than any other method.
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, will attend the fall 2019 session of ACOOG from October 3-6 in Columbus, OH to share the benefits SneakPeek Clinical can bring to the patients of obstetricians and gynecologists.
Gateway Genomics Ranks 236 in the Inc. 500 Fastest-Growing Private Companies in America List for 2019
Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the 38th annual Inc. 500|5000 list of fastest growing private companies, in the first year the company has been eligible to apply. To qualify, companies must have been founded and generating revenue by March 31, 2015. Ranking in the list is determined by the percentage revenue growth from 2015 to 2018, with minimums set for each year. With 1,786% revenue growth from 2015 to 2018, Gateway Genomics ranked #236 in the list, and #23 in the Health sector.
Breakthrough Publication Shows Gateway Genomics SneakPeek Early Gender DNA Blood Test Identifies Fetal Sex at 8 Weeks into Pregnancy with 99.1% Accuracy
Gateway Genomics, a leading developer of genomic tests that give families insight into their future children, announces a new publication titled, “Accurate Fetal Sex Determination from Maternal Blood at 8 Weeks Gestation” in the International Journal of Pregnancy & Child Birth. In the study, DNA blood samples were collected from 108 women at an average gestational age of 8 weeks. Cell-free fetal DNA (cffDNA) was extracted and run through the SneakPeek test process, which looks for male chromosomes. If male chromosomes were detected in the fetal DNA found in mom’s blood, the baby was identified as male. If not, the baby was identified as female. Of 51 male-bearing pregnancies, SneakPeek correctly identified all 51, demonstrating 100% sensitivity for Y-chromosome DNA detection, even at this early stage. Of 57 female-bearing pregnancies, SneakPeek correctly identified 56, leading to a 99.1% accuracy rate for the overall study.
Gateway Genomics, leading developer of prenatal and pediatric genetic tests, announces sales of over 100,000 SneakPeek Early Gender DNA tests as of this month. SneakPeek is the first non-invasive prenatal test (NIPT) designed solely to determine fetal sex, providing an easy way for families to learn the gender of their baby as early as 9 weeks into pregnancy. The test is available through two channels: 1) An at-home version that lets consumers self-collect a DNA blood sample from the comfort of their home and mail back to SneakPeek Labs for analysis, and 2) A clinical version through participating facilities that collects the sample through a standard blood draw and sends it to SneakPeek Labs for testing. Both options can provide gender results within 1-2 days from sample collection.
Gateway Genomics Announces Expanding Office and Research Space to Accommodate Increased Demand for SneakPeek DNA Test
Gateway Genomics, a leading developer of prenatal and pediatric genetic tests, announces an office expansion, effectively doubling its space from 2,500 to 5,000 square feet.
Gateway Genomics SneakPeek Noninvasive Prenatal Test (NIPT) Identifies Gender with Cell-free Fetal DNA from Microvolumes of Self-collected Maternal Blood
Gateway Genomics, a leading developer of genomic tests that give families insight into their future children, announces a new publication titled, “Self-Collection of Maternal Blood for Fetal Sex Determination Using Cell-Free DNA” in the journal of Pregnancy and Child Health. Previous studies had only shown early gender determination using venous blood. When translated into practice, this meant women had to travel to licensed phlebotomists to have their blood drawn intravenously, which limited access to noninvasive prenatal tests. The new paper opens the possibility for women to self-collect as little as 7-10 drops of blood from a finger stick in the comfort of their home and learn the gender of their unborn baby. In this study, fetal sex was determined with 100% accuracy.
SneakPeek Clinical Greater Than 99% Accurate for Fetal Sex at 9 Weeks into Pregnancy – SneakPeek Early Gender Test Results Published in Journal of Pregnancy and Child Health
LA JOLLA, Calif.–(BUSINESS WIRE)–The Journal of Pregnancy and Child Health published a SneakPeek Clinical study that is exciting news for low-risk pregnant women seeking to know the gender of their baby. Typically, only high-risk pregnancies are eligible for insurance coverage for prescription-based NIPTs. As for everyone else, the cost of entry can be in the thousands. With this new publication, SneakPeek proves that no longer has to be.